Citations

Clear

966 citation(s) found for "WONG, R".

Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity
Harmon, Charles S., Cooling, Laura , Connelly‐Smith, Laura , Mann, Steven A. , Pham, Huy P. , Marques, Marisa B. , Schlueter, Annette J. , Case, Rosemary, King, Karen E., Cataife, Guido, Wu, Yanyun , Wong, Edward C.C. , Winters, Jeffrey L , Pagano, Monica B. , Winters, Jeffrey L. , Pham, Huy P , Schlueter, Annette J , Marques, Marisa B

Mayo Clinic

Transfusion | September 7, 2016 | Volume: 56 | Issue: 11 | Pages: 2848-2856

10.1111/trf.13795 | PMID 27600855 Get It

BACKGROUNDHydroxyethyl starch (HES) is reportedly associated with an increased risk of renal failure and death when used for fluid resuscitation in critically ill patients. HES can be used during therapeutic leukocytapheresis (TL) procedures to enhance cell separation. The purpose of this study was to evaluate the occurrence of adverse events associated with HES during TL procedures.STUDY DESIGN AND METHODSWe performed a retrospective review of patients who underwent TL with and without HES in the period 2009 to 2013 at six academic medical institutions.RESULTSA difference‐in‐difference regression analysis was used to estimate the mean change before and after TL in selected outcomes in the HES group relative to the average change in the non‐HES group. Selected outcomes included serum creatinine, estimated glomerular filtration rate (eGFR), and white blood cell (WBC) count. A total of 195 patients who underwent 278 TL procedures were studied. We found no significant differences in serum creatinine levels and eGFR on Days 1 and 7 after TL procedure between patients who received and those who did not receive HES. The rate of adverse events and overall and early mortality were similar in both groups. Patients with acute myeloid leukemia who received HES had greater WBC reduction when HES was used. Additionally, patients who received HES had improvement in pulmonary leukostasis symptoms.CONCLUSIONHES, used at low doses during TL procedures, was not associated with adverse events previously ascribed to its use as a volume expander.
Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma
Buas, Matthew F. , He, Qianchuan , Johnson, Lisa, Onstad, Lynn , Levine, David , Gharahkhani, Puya , Palles, Claire , Lagergren, Jesper , Fitzgerald, Rebecca C. , Ye, Weimin , Caldas, Carlos , Bird, Nigel C., Shaheen, Nicholas J. , Gammon, Marilie D. , Wu, Anna H. , Hardie, Laura J. , Liu, Geoffrey , Iyer, Prassad, Corley, Douglas A. , Chow, Wong‐Ho , Prenen, Hans , Chegwidden, Laura , Love, Sharon , Attwood, Stephen E., MacDonald, David , Harrison, Rebecca , Barr, Hugh , Caestecker, John de , Tomlinson, Ian , Jankowski, Janusz , Whiteman, David C. , MacGregor, Stuart , Vaughan, Thomas L. , Madeleine, Margaret M. , Thrift, Aaron P. , Bernstein, Leslie , Pharoah, Paul D.P. , Risch, Harvey A. , Moayyedi, Paul , Watson, Peter J. , Caldas, Carlos , Liu, Geoffrey , Gharahkhani, Puya , MacGregor, Stuart , Lagergren, Jesper , Hardie, Laura J , Ye, Weimin , Love, Sharon B , deCaestecker, John , Prenen, Hans , Palles, Claire , Jankowski, Janusz A , Whiteman, David C , Buas, Matthew F

Mayo Clinic

Gut | August 2, 2016 | Volume: 66 | Issue: 10 | Pages: 1739-1747

10.1136/gutjnl-2016-311622 | PMID 27486097 Get It

Objective Oesophageal adenocarcinoma (OA) incidence has risen sharply in Western countries over recent decades. Local and systemic inflammation is considered an important contributor to OA pathogenesis. Established risk factors for OA and its precursor, Barrett's oesophagus (BE), include symptomatic reflux, obesity and smoking. The role of inherited genetic susceptibility remains an area of active investigation. Here, we explore whether germline variation related to inflammatory processes influences susceptibility to BE/OA. Design We used data from a genomewide association study of 2515 OA cases, 3295 BE cases and 3207 controls. Our analysis included 7863 single-nucleotide polymorphisms (SNPs) in 449 genes assigned to five pathways: cyclooxygenase (COX), cytokine signalling, oxidative stress, human leucocyte antigen and nuclear factor-κB. A principal components-based analytic framework was employed to evaluate pathway-level and gene-level associations with disease risk. Results We identified a significant signal for the COX pathway in relation to BE risk (p=0.0059, false discovery rate q=0.03), and in gene-level analyses found an association with microsomal glutathione-S-transferase 1 (MGST1); (p=0.0005, q=0.005). Assessment of 36 MGST1 SNPs identified 14 variants associated with elevated BE risk (q<0.05). Four of these were subsequently confirmed (p<5.5×10−5) in a meta-analysis encompassing an independent set of 1851 BE cases and 3496 controls, and are known strong expression quantitative trait loci for MGST1. Three such variants were associated with similar elevations in OA risk. Conclusions This study provides the most comprehensive evaluation of inflammation-related germline variation in relation to risk of BE/OA and suggests that variants in MGST1 influence disease susceptibility.
Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee
Dunbar, Nancy M. , Raval, Jay S. , Johnson, Andrew D. , Abikoff, Cori, Adamski, Jill , Cooling, Laura , Kim, Haewon C., Morgan, Shanna, Schmidt, Amy E. , Sloan, Steven R. , Su, Leon , Szczepiorkowski, Zbigniew M. , West, F. Bernadette, Wong, Edward C.C. , Schneiderman, Jennifer , Grossman, Brenda J. , Marques, Marisa B. , Dunbar, Nancy M , Raval, Jay S

Mayo Clinic

Journal of Clinical Apheresis | July 21, 2016 | Volume: 32 | Issue: 4 | Pages: 215-223

10.1002/jca.21486 | PMID 27442906 Get It

AbstractBackgroundAlthough many apheresis centers offer extracorporeal photopheresis (ECP), little is known about current treatment practices.MethodsAn electronic survey was distributed to assess ECP practice internationally.ResultsOf 251 responses, 137 met criteria for analysis. Most respondents were from North America (80%). Nurses perform ECP at most centers (84%) and the majority of centers treat adults only (52%). Most centers treat fewer than 50 patients/year (83%) and perform fewer than 300 procedures/year (70%). Closed system devices (XTS and/or Cellex) are used to perform ECP at most centers (96%). The most common indications for ECP are acute/chronic skin graft versus host disease (89%) and cutaneous T‐cell lymphoma (63%). The typical wait time for ECP treatment is less than 2 weeks (91%). Most centers do not routinely perform quality control assessment of the collected product (66%). There are device‐specific differences in treatment parameters. For example, XTS users more frequently have a minimum weight limit (P = 0.003) and use laboratory parameters to determine eligibility for treatment (P = 0.03). Regardless of device used, the majority of centers assess the clinical status of the patient before each procedure. Greater than 50% of respondents would defer treatment for hemodynamic instability due to active sepsis or heart failure, positive blood culture in the past 24 h or current fever.ConclusionThis survey based study describes current ECP practices. Further research to provide evidence for optimal standardization of patient qualifications, procedure parameters and product quality assessment is recommended.
Incidence of Pocket Infection Postcardiac Device Implantation Using Antibiotic versus Saline Solution for Pocket Irrigation
Lakshmanadoss, Umashankar, Nuanez, Bonita, Kutinsky, Ilana , Khalid, Rizwan, Haines, David E. , Wong, Wai Shun

Mayo Clinic

Pacing and Clinical Electrophysiology | July 21, 2016 | Volume: 39 | Issue: 9 | Pages: 978-984

10.1111/pace.12920 | PMID 27440320 Get It

BackgroundPreprocedure systemic antibiotic prophylaxis reduces infections in patients undergoing cardiac implantable electronic devices (CIEDs) implantations. Whether pocket irrigation with antibiotic solution offers any advantage over saline solution in CIED implantation is unknown.MethodsRecords from 327 consecutive patients who underwent CIED implantation by three operators from February 2011 to January 2014 were reviewed. From February 2011 to January 2012, the antibiotic solution was used for pocket irrigation; from February 2012 to January 2014, saline solution was used. All patients received preprocedural IV antibiotics. Baseline demographics, comorbidities, lab data, and occurrence of any pocket infection postimplant were collected.ResultsThere were 118 and 209 patients in the antibiotic solution and saline solution group, respectively. A total of four (1.2%) patients had CIED infection: two in the antibiotic solution group and two in the saline solution group. Median time to infection from implant date was 81.5 ± 35 days. Two patients (50%) had infection after first device implantation. Of the four patients, one had positive blood culture, three had positive pocket cultures, one had lead vegetation, one underwent pocket exploration, and all of them had devices/leads extracted, with reimplantation on the contralateral side. No mortality was observed due to infectious complications.ConclusionWhen compared to pocket irrigation in the antibiotic solution group, the saline solution group was not associated with increased incidence of infectious complications after CIED implantation. The use of saline solution pocket irrigation alone may be used in CIED pocket irrigation periprocedurally. Further evaluation in larger randomized trials is needed.
Drug Class Combination–Associated Acute Kidney Injury
Rivosecchi, Ryan , Kellum, John A. , Dasta, Joseph F. , Armahizer, Michael , Bolesta, Scott , Buckley, Mitchell S. , Frazee, Erin N., Johnson, Heather , Murugan, Raghavan , Smithburger, Pamela L. , Gill, Sandra L., Kane‐Gill, Sandra L. , Dzierba, Amy L. , Frazee, Erin N., Kim, Catherine , Wong, Adrian , Kane-Gill, Sandra L , Kellum, John A

Mayo Clinic

Annals of Pharmacotherapy | July 7, 2016 | Volume: 50 | Issue: 11 | Pages: 953-972

10.1177/1060028016657839 | PMID 27389325 Get It

Objective: To evaluate the quality of available evidence of drug class combinations and their association with the development of acute kidney injury (AKI). Data Sources: A search of MEDLINE and Embase databases was completed using the following terms: “risk factor AND (acute kidney injury or acute kidney failure) AND (drug or medication).” Study Selection and Data Extraction: Inclusion criteria were the following: English language, full-text availability, and at least 1 drug-combination. Each citation was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria. The literature was evaluated using the quality of evidence component of GRADE. No standardized definition of AKI was applied throughout.. Data Synthesis: Out of 2139 total citations, 151 were assessed for full-text review, with 121 citations (6%) meeting inclusion criteria, producing76 unique drug class combinations. Overall, 56 combinations (73.7%) were considered very low quality; 12 (15.8%) were considered low quality. There were 8 (10.5%) of moderate quality, and no combination was considered high quality. 58 (76%) combinations that had a single citation,with a mean of 1.6 citations per drug class combination. The combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics was reported in 10 citations, the largest number of citations. Conclusions: Our study demonstrates a lack of well-designed studies addressing drug class combination–associated AKI. The combination of NSAIDs and diuretics with or without additional renin-angiotensin aldosterone agents had the strongest level of evidence. Despite limitations, the information included in this review may result in additional scrutiny about combining certain individual nephrotoxic drugs.
Abstract P2-05-21: The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer
Wong, S N, Reeder, Alex, Anthony, SP, Robert, NJ, Northfelt, DW, Jahanzeb, Mohammad , Vocila, Linda, Wulfkuhle, Julia , Dunetz, Bryant, Aldrich, Jessica, Craig, D. Shriver, Petricoin, EF, Carpten, John D. , Pierobon, Massimiliano , Wong, S, Aldrich, Jessica, Byron, Sara A. , Liotta, Lance A.

Mayo Clinic

Cancer Research | May 20, 2016 | Volume: 76 | Issue: 4_Supplement | Pages: P2-05-21-P2-05-21

10.1158/1538-7445.sabcs15-p2-05-21 Get It

Abstract Background: The identification of organ-specific targetable signatures may help design more effective treatment for patients with metastatic breast cancer (MBC). We took a multi-OMIC approach to assess whether the AKT-mTOR pathway is globally activated during metastatic progression or whether it represents an organ-specific target. Methods: Snap frozen biopsies from 25 MBC patients enrolled in a prospective phase II trial were used. Sites of metastasis were classified as liver (n=8) and others (n=17), the latter including cutaneous, lung, lymph nodes, and intra-abdominal lesions. Signaling analysis of the 25 cases was performed using Reverse Phase Protein Microarray (RPPA) coupled with Laser Capture Microdissection. Activation of the AKT-mTOR pathway was quantified as phosphorylation of AKT (S473) and the mTOR target p70S6 (T389). Matched exome (WES) and RNASeq data were available for 17 of 25 patients, five with liver metastases. Sequencing data was processed using an in-house developed pipeline to identify somatic events including coding mutations, copy number alterations, gene fusions, and differential expression. Activation of the AKT-mTOR pathway and sequencing data were compared between hepatic and non-hepatic lesions using an integrated RPPA and genomic approach. Results: Among liver metastases, AKT was activated in 4 of the 8 (50.0%) patients, while 6 of the 8 cases (75.0%) showed activation of p70S6. Sequencing data revealed mutation of PIK3CA in 4 of the 5 liver metastases (80.0%). Three of the PIK3CA mutated specimens with catalytic domain mutations (codons 1023 and 147) demonstrated co-activation of AKT and p70S6, while the fourth case, containing a helical domain mutation (E542K), had activation of p70S6 only. The PIK3CA wild-type liver metastasis demonstrated low activation of AKT and p70S6. For non-hepatic metastases AKT was activated in 2 of the 17 cases (11.8%) and p70S6 in 5 of the 17 patients (29.4%). Discussion: Although these results need further validation, activation of the AKT-mTOR pathway appears to be a hepatic specific signature in MBC and could be used for the selection of targeted agents for hepatic lesions. Citation Format: Pierobon M, Wong S, Reeder A, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Petricoin EF, Carpten J. The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-21.
Faculty Opinions recommendation of Novel intragastric trocar placed by PEG technique permits endolumenal use of rigid instruments to simplify complex endoscopic procedures.
Song, Louis M. Wong Kee

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 28, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726308870.793517356 Get It

Smoking Cessation: The Role of the Anesthesiologist
Yousefzadeh, Amir, Chung, Frances , Wong, David T. , Wong, Jean , Warner, David O. , Wong, Jean

Mayo Clinic

Anesthesia & Analgesia | April 22, 2016 | Volume: 122 | Issue: 5 | Pages: 1311-1320

10.1213/ane.0000000000001170 | PMID 27101492 Get It

Smoking increases the risk of postoperative morbidity and mortality. Smoking cessation before surgery reduces the risk of complications. The perioperative period may be a “teachable moment” for smoking cessation and provides smokers an opportunity to engage in long-term smoking cessation. Anesthesiologists as the perioperative physicians are well-positioned to take the lead in this area and improve not only short-term surgical outcomes but also long-term health outcomes and costs. Preoperative interventions for tobacco use are effective to reduce postoperative complications and increase the likelihood of long-term abstinence. If intensive interventions (counseling, pharmacotherapy, and follow-up) are impractical, brief interventions should be implemented in preoperative clinics as a routine practice. The “Ask, Advise, Connect” is a practical strategy to be incorporated in the surgical setting. All anesthesiologists should ask their patients about smoking and strongly advise smokers to quit at every visit. Directly connecting patients to existing counseling resources, such as telephone quitlines, family physicians, or pharmacists using fax or electronic referrals, greatly increases the reach and the impact of the intervention.